Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase I drugs for Laryngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ipatasertib LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ipatasertib overview

Ipatasertib (RG-7440/GDC-0068) is under development for the treatment of  metastatic solid tumors including advanced or metastatic HER2-positive breast cancer, epithelial ovarian cancer, fallopian tube cancer, head and neck squamous cell carcinoma (HNSCC), oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, oral cavity (mouth) cancer, paranasal sinus and nasal cavity cancer  peritoneal cancer, castration-resistant prostate cancer in previously untreated patients and also patients treated with docetaxel chemotherapy, metastatic and hormone receptor-positive, HER2-negative breast cancer, glioblastoma mulitforme, melanoma, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The drug candidate is administered orally in the form of tablets and capsules.  It is a small molecule with antineoplastic activity. Ipatasertib targets the serine/threonine protein kinase Akt (protein kinase B). It was also under development for neoadjuvant triple negative breast cancer, endometrial cancer and prostate cancer.

 oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, oral cavity (mouth) cancer, paranasal sinus and nasal cavity cancer

Genentech USA overview

Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

For a complete picture of Ipatasertib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.